The company said that the 9, 10 and 12mm diameters of Maris Plus are already marketed for the iliac artery. The Maris Plus stent features a cell design at the stent ends. This allows physicians to place several stents in series without stiffening the artery in the overlap region.
Maris Plus becomes the sixth stent platform marketed by the company for the treatment of Peripheral Arterial Disease (PAD), optimising visibility and flexibility for the physician.
Stefan Widensohler and Andrea Venturelli, co-founders of Invatec, said: “It was our goal to offer dedicated stent geometries to respond to the different needs of the iliac and SFA arteries. With the Maris Plus, we have created a stent with an overlap region that allows two stents to act like one in the femoral artery.
“The distinct design provides excellent flexibility, fracture resistance, and tailored deployment. Additionally, larger and fully integrated tantalum markers greatly enhance visibility for the physician.”
